Inhibitors of aspartyl protease

Details Inhibitors of aspartyl protease Inhibitors of aspartyl protease

2003-07-02

2008-10-28

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S438000, C558S390000, C560S013000, C560S017000, C560S019000, C560S147000, C560S155000, C514S464000, C514S523000, C514S529000

Reexamination Certificate

active

07442718

ABSTRACT:
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

REFERENCES:
patent: 4629724 (1986-12-01), Ryono et al.
patent: 5723490 (1998-03-01), Tung
patent: 5843946 (1998-12-01), Vasquez et al.
patent: 6143747 (2000-11-01), Freskos et al.
patent: 0 159 156 (1985-10-01), None
patent: 0 594 540 (1994-04-01), None
patent: WO94/05639 (1994-03-01), None
patent: WO9404492 (1994-03-01), None
patent: WO94/10136 (1994-05-01), None
patent: WO95/06030 (1995-03-01), None
patent: WO95/07269 (1995-03-01), None
patent: WO95/09843 (1995-04-01), None
patent: WO95/14016 (1995-05-01), None
patent: WO95/32185 (1995-11-01), None
patent: WO96/33187 (1996-10-01), None
A.K. Ghosh et al., “Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligangs and (R)- (Hydroxyethylamino)sulfonamide Isostere,”Bioorg. Med. Chem. Lett., 8, pp. 687-690 (1998).
S. J. Hays et al., “Synthesis of cis-4-(Phosphonooxy)-2-piperidinecarboxylic Acid, an N-Methyl-D-aspartate Antagonist,”J. Org. Chem., 56, pp. 4084-4086 (1991).
Y. Kiso et al., “‘O→N Intramolecular Acyl Migration’-type Prodrugs of Tripeptide Inhibitors of HIV Protease,”Peptides: Chemistry, Structure and Biology, 61, pp. 157-159 (1996).
A.C. Nair et al., “A Computational Study of the Resistance of HIV-1 Aspartic Protease to the Inhbitors ABT-538 and VX-478 and Design of New Analogues,”Biochem. Biophys. Res. Commun., 242, pp. 545-551 (1998).
J.W. Perich et al., “The Synthesis of Multiple O-Phosphoseryl-Containing Peptides via Phenyl Phosphate Protection,”J. Org. Chem., 53, pp. 4103-4105 (1988).
M.S. Plummer et al., “Design of Peptidomimetic Ligands for the pp60srcSH2 Domain,”Bioorganic&Medicinal Chemistry, 5, pp. 41-47 (1997).
S. Yamaguchi et al., “Synthesis of HIV Protease Dipeptide Inhibitors and Prodrugs,”Peptide Chemistry 1996, pp. 297-300 (1997).
Banker et al.,Modern Pharmaceutics, pp. 627-629 (1996).
C.T. Baker et al., “Design, Synthesis and Conformational Analysis of A Novel Series of HIV Protease Inhbitors,”Bioorg. &Med. Chem. Lett., vol. 8, pp. 3631-3636 (1998).

Affiliated with

Also associated with

Rating

Inhibitors of aspartyl protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of aspartyl protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of aspartyl protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4007554